Skip to content

menu

Pharma in Brief logo
Current Page:HomeAboutContact
Search
Close
Pharmaceuticals and life sciencesIntellectual propertyLife sciences and healthcare
View topics Archives
Subscribe

Pharma in Brief

Canada expanding national pharmacare and rare disease drug coverage

Photo of Sarah PenningtonPhoto of Paul JorgensenPhoto of Kristin Wall
By Sarah Pennington, Paul Jorgensen & Kristin Wall on March 27, 2025

March 2025 saw a flurry of developments in Canada’s emerging national funding systems of drugs for rare diseases and pharmacare. All of Canada’s 13 provinces and territories have now reached bilateral agreements with the federal government to cover certain drugs…

Subscribe to Pharma in Brief

Subscribe to this publication

British Columbia becomes second province to sign pharmacare agreement

Photo of Sarah PenningtonPhoto of Paul JorgensenPhoto of Kristin Wall
By Sarah Pennington, Paul Jorgensen & Kristin Wall on March 7, 2025

On March 6, 2025, British Columbia became the second province to announce the signing of a pharmacare agreement with Canada’s federal government. Manitoba was the first province to do so, on February 27, 2025 (our report here).

British Columbia’s

…

Agile licensing, risk, biologics, and more: Wide-ranging amendments to Canada’s drug and medical device regulations

Photo of Sarah PenningtonPhoto of Paul JorgensenPhoto of Kristin Wall
By Sarah Pennington, Paul Jorgensen & Kristin Wall on March 3, 2025

Canada has made wide-ranging amendments to the Food and Drug Regulations (FDR) and the Medical Devices Regulations (MDR). The amendments are intended to deliver on Health Canada’s modernization commitments, codify long-standing policies and practices, and implement…

National pharmacare in Canada: First-ever funding agreement announced

Photo of Sarah PenningtonPhoto of Paul JorgensenPhoto of Kristin Wall
By Sarah Pennington, Paul Jorgensen & Kristin Wall on February 27, 2025

On February 27, 2025, the governments of Canada and of the Province of Manitoba announced the first-ever national pharmacare funding agreement. The two governments also announced a funding agreement under the National Strategy for Drugs for Rare Diseases.

Pharmacare

…

Drug shortages: New requirements proposed for the Food and Drug Regulations

Photo of Julia KafatoPhoto of Sarah PenningtonPhoto of Paul JorgensenPhoto of Kristin Wall
By Julia Kafato, Sarah Pennington, Paul Jorgensen & Kristin Wall on February 12, 2025

Health Canada has proposed additional regulations intended to prevent, mitigate, and respond to drug shortages. The proposed amendments to the Food and Drug Regulations (Regulations) include new requirements for drug market authorization holders to develop shortage prevention and…

Pharma in Brief’s 2024 Year in Review and Trends for 2025

Photo of Kristin WallPhoto of Christopher A. GuerreiroPhoto of Paul JorgensenPhoto of Sarah Pennington
By Kristin Wall, Christopher A. Guerreiro, Paul Jorgensen & Sarah Pennington on February 3, 2025

2024 saw no shortage of headlines in the Canadian pharma space. Here we look back on the year’s most notable legal and regulatory developments and look forward to areas to watch in 2025.

1. National pharmacare comes to Canada

In…

Drug Pricing Update: PMPRB launches consultation on Draft Guidelines for price review

Photo of Christopher A. GuerreiroPhoto of Kristin Wall
By Christopher A. Guerreiro & Kristin Wall on December 20, 2024

The Patented Medicine Prices Review Board (PMPRB or Board) has released a draft of its new price review Guidelines (the Draft Guidelines) for consultation. The Draft Guidelines outline a proposed new price-review process for Board Staff, with…

Federal Court declares patent ineligible for listing during PM(NOC) infringement action

Photo of Pardeep HeirPhoto of Christopher A. GuerreiroPhoto of Kristin Wall
By Pardeep Heir, Christopher A. Guerreiro & Kristin Wall on December 16, 2024

The Federal Court (FC) has provided fresh guidance on applying the test for challenging patent-listing eligibility in an infringement action under the Patented Medicines (Notice of Compliance) Regulations (the Regulations). Granting the delisting motion before it, the…

Recent developments in Canadian national pharmacare and funding for drugs for rare diseases

Photo of Sarah PenningtonPhoto of Paul JorgensenPhoto of Kristin Wall
By Sarah Pennington, Paul Jorgensen & Kristin Wall on December 10, 2024

Canada’s emerging national systems of pharmacare and public funding for drugs for rare diseases (DRDs) had key developments last week. On December 4, the Minister of Health (Minister) asked Canada’s Drug Agency-L’Agence des médicaments du Canada…

Federal Court denies samples for testing infringement of biologic process patent

Photo of Paul JorgensenPhoto of Kristin Wall
By Paul Jorgensen & Kristin Wall on December 5, 2024

The Federal Court recently refused to order a defendant to produce samples of cell culture because there was no “reasonable possibility” that testing the samples would yield evidence of patent infringement.  In pharmaceutical patent cases, testing samples of a defendant’s…

Post navigation

Older Posts 
The latest from our blog network
Norton Rose Blog Network
Securities litigation and enforcement

Artificial Intelligence Fraud: Beware of Succumbing to Technology’s Latest Fad

May 23, 2025
Global Regulation Tomorrow

EP legislative resolution on proposed Regulation amending CRR requirements for SFTs under NSFR

May 23, 2025
Global Regulation Tomorrow

Response to the FCA Credit Information Market Study

May 23, 2025
Global Regulation Tomorrow

Handbook Notice 130

May 23, 2025
Global Regulation Tomorrow

SEC Leaders Emphasize Need for Economic Rigor in Rulemaking

May 23, 2025
Global Regulation Tomorrow

SEC Commissioners Debate New Approach to Innovation, Rulemaking and Crypto

May 23, 2025
Global Regulation Tomorrow

Task force on Monetary Policy Examines Treasury Market Volatility

May 23, 2025
Global Workplace Insider

Italy employment law update: Influencer contracts

May 23, 2025
Global Regulation Tomorrow

PRA publishes policy statement on SME infrastructure lending adjustments to Pillar 2A

May 23, 2025
View the Norton Rose blog network

Pharma in Brief

LinkedIn Twitter Facebook RSS YouTube
Published by
Norton Rose Fulbright LLP logo
DisclaimerPrivacy policy

About

Stay up-to-date with legal and regulatory developments affecting the pharmaceutical industry. Pharma in Brief provides timely updates with a focus on the key take-away you need to know.

Read more

Topics

Archives

Copyright © 2025, Norton Rose Fulbright LLP. All rights reserved.